OC-70: CLINICAL TRIAL, GCP AND CERTIFICATION IN NATURAL PRODUCTS

Excerpt:


J Pharm Pharmacogn Res 3(suppl. 1): S82, 2015 Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba. Oral Communication OC-70: CLINICAL TRIAL, GCP AND CERTIFICATION IN NATURAL PRODUCTS Orta D. Centro para el Control Estatal de Medicamentos, Equipos … Continue reading OC-70: CLINICAL TRIAL, GCP AND CERTIFICATION IN NATURAL PRODUCTS

J Pharm Pharmacogn Res 3(suppl. 1): S82, 2015

Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.

Oral Communication

OC-70: CLINICAL TRIAL, GCP AND CERTIFICATION IN NATURAL PRODUCTS

Orta D.

Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED), Calle 5ta A entre 60 y 62, Reparto Miramar, Playa, La Habana, Cuba, C.P.10300. Telef: (537) 2164100, 2164348, 2164347. E-mail: deybis@cecmed.cu

 

The basic function Clinical Trial Authorization in CECMED guarantee protection, benefits, rights and safety of individuals (healthy and diseased) involved in clinical research, as well as a design, conduct and analysis according to scientific principles. The scope includes drugs, biological and natural products. Because of the importance and need to strengthen the clinical development in natural products, the aspects of clinical trials are discussed including the implementation of Good Clinical Practice (GCP) and Certification of GCP in clinical sites that perform these studies. This allows the analysis about knowledge, control and level elevated of exigency of direct and stable way on quality assurance and compliance with GCP. Twenty years of experience CECMED, Cuban Regulatory Authority (MRA), in developing guidelines GCP (1992, 1995 and 2000) with their implementation and control for the National Program of Inspections to Clinical Trials has allowed develop a Certification System for GCP to evaluate and qualify the clinical sites that carry out the requirements for this certification. Since 2008, the regulation 52-08 Requirements for GCP Certification to Sites and/or Clinical Services that perform clinical trials was implemented. This normative started up the GCP Certification System to achieve the identified institutions that met the conditions were certified and prove to the international scientific community that develops and evaluates drugs, credibility and reliability in compliance with GCP and its implementation in Cuba. To evaluate their implementation has been compiled information compliance inspection program for clinical trials and related system between 2008 and 2012, including: inspections, type, institutions, results and issued documents. The training and preparation of institutions and professionals to obtain certification was evaluated. In addition took place the presentation and discussion for this topic in national and international activities. Finally, you can limit the implementation of GCP Certification System has allowed systematic evaluation of compliance GCP in  the institutions involved, the responsibilities of the parties and level of knowledge on the topic and continuous improvement of the activity. Creates the basis for the country to ensure GCP compliance in institutions and recognition, reliability and national and international credibility of this condition.

Citation Format: Orta D (2015) Clinical trial, GCP and certification in natural products. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S82. Abstract nr OC-70.
Toxicity evaluation of Ruta angustifolia leaves ethanolic extract
J. Pharm. Pharmacogn. Res., vol. 11, no. 3, pp. 437-447, May-June 2023. DOI: https://doi.org/10.56499/jppres23.1609_11.3.437 Original Article Acute and repeated dose 28-day oral toxicity of Ruta angustifolia Pers. leaves ethanolic extract in Wistar rats [Toxicidad oral aguda y por dosis repetidas durante 28 días del extracto etanólico de hojas de Ruta angustifolia Pers. en ratas Wistar] Tutik … Continue reading Toxicity evaluation of Ruta angustifolia leaves ethanolic extract
Adolescents in Indonesia and COVID-19 pandemic
J. Pharm. Pharmacogn. Res., vol. 11, no. 3, pp. 426-436, May-June 2023. DOI: https://doi.org/10.56499/jppres22.1560_11.3.426 Original Article Perception, mental health, and social media exposure on adolescents in Indonesia during COVID-19 pandemic [Percepción, salud mental y exposición a los medios sociales en adolescentes de Indonesia durante la pandemia de COVID-19] Efa Nugroho1*, Alfiana Ainun Nisa1, Widya Hary Cahyati1, … Continue reading Adolescents in Indonesia and COVID-19 pandemic
Decaffeinated green tea and coffee extracts and metabolic syndrome
J. Pharm. Pharmacogn. Res., vol. 11, no. 3, pp. 414-425, May-June 2023. DOI: https://doi.org/10.56499/jppres23.1593_11.3.414 Original Article Decaffeinated green tea and green coffee extracts as metformin’s add-on enhance metabolic syndrome risk factors and improve the cardiac insulin-gene-related pathway [Extractos de té verde y café verde descafeinados como complemento de la metformina mejoran los factores de riesgo del … Continue reading Decaffeinated green tea and coffee extracts and metabolic syndrome

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio